Late dosing of common luteinizing hormone-releasing hormone (LHRH) agonists used for androgen deprivation therapy (ADT) in prostate cancer occurs frequently, a researcher reported. Late dosing was ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results